Shots:
- The P-III (CONVOKE) trial assessed CT-155 (BI 3972080) vs a digital control app as an adjunct to SoC antipsychotic therapy in pts (≥18yrs.) with experiential negative symptoms of schizophrenia
- Trial met its 1EP with 6.8 vs 4.2-point improvement in negative symptom severity on the CAINS-MAP at 16wks., achieving a Cohen’s D of -0.36; most subjects used their assigned app through Wk. 15, with median activity completion of 76 vs 92 days out of 112 possible study days, indicating CT-155’s benefits stemmed from its content
- CT-155 is a prescription digital therapeutic that is also being evaluated in Enspirus trial for pts with experiential negative symptoms of schizophrenia in a real-world-like setting
Ref: Boehringer Ingelheim| Image: Boehringer Ingelheim & Click Therapeutics | Press Release
Related News:- Boehringer Ingelheim Reports the US FDA’s Approval of Jascayd (Nerandomilast) for Idiopathic Pulmonary Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
